Gross Profit Trends Compared: Pfizer Inc. vs Takeda Pharmaceutical Company Limited

Pfizer vs Takeda: A Decade of Gross Profit Trends

__timestampPfizer Inc.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 2014400280000001256834000000
Thursday, January 1, 2015392030000001271973000000
Friday, January 1, 2016404950000001173296000000
Sunday, January 1, 2017413060000001274610000000
Monday, January 1, 2018423990000001437534000000
Tuesday, January 1, 2019415310000002201424000000
Wednesday, January 1, 2020332160000002203504000000
Friday, January 1, 2021504670000002462160000000
Saturday, January 1, 2022659860000002783406000000
Sunday, January 1, 2023288090000002832257000000
Monday, January 1, 2024457760000002832257000000
Loading chart...

Unlocking the unknown

Gross Profit Trends: Pfizer Inc. vs Takeda Pharmaceutical

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. Over the past decade, Pfizer Inc. and Takeda Pharmaceutical Company Limited have showcased distinct trajectories in their gross profit margins. From 2014 to 2023, Pfizer's gross profit fluctuated, peaking in 2022 with a remarkable 65% increase from its 2014 figures. However, 2023 saw a significant dip, highlighting the volatility in the market.

Conversely, Takeda Pharmaceutical demonstrated a more consistent upward trend, with its gross profit nearly doubling from 2014 to 2023. This growth underscores Takeda's strategic positioning and resilience in the global market. Notably, 2019 marked a pivotal year for Takeda, with a substantial 54% increase in gross profit, likely driven by strategic acquisitions and expansions.

These insights provide a window into the financial health and strategic maneuvers of two pharmaceutical giants, offering valuable lessons for investors and industry stakeholders.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025